Vipul Lakhani, MD Oregon Medical Group Endocrinology
|
|
- Rodney Horton
- 6 years ago
- Views:
Transcription
1 Vipul Lakhani, MD Oregon Medical Group Endocrinology
2 Disclosures None
3 Objectives Be able to diagnose diabetes and assess control Be able to identify appropriate classes of medications for diabetes treatment Begin to manage diabetes and comorbidities
4 Epidemiology of Diabetes Diabetes affects 29.1 million people of all ages 9.3% of the U.S. population Diagnosed: 21 million Undiagnosed: 8.1 million Leading cause of kidney failure, nontraumatic lower-limb amputation, new cases of blindness among adults Major cause of heart disease and stroke Seventh leading cause of death National Diabetes Statistics Report, Available at:
5 County-Level Estimates of Diagnosed Diabetes (%), Adults 20 years, 2008 Percent >
6 Number of Americans with Diagnosed Diabetes,
7 STANDARDS OF MEDICAL CARE IN DIABETES 2015
8 ADA Evidence Grading System for Clinical Practice Recommendations Level of Evidence A B C E Description Clear or supportive evidence from adequately powered well-conducted, generalizable, randomized controlled trials Compelling nonexperimental evidence Supportive evidence from well-conducted cohort studies or case-control study Supportive evidence from poorly controlled or uncontrolled studies Conflicting evidence with the weight of evidence supporting the recommendation Expert consensus or clinical experience ADA. Diabetes Care 2015;38(suppl 1):S2; Table 1
9 Recommendations: Strategies for Improving Diabetes Care Care should be aligned with components of the Chronic Care Model to ensure productive interactions between a prepared proactive practice team and an informed activated patient A When feasible, care systems should support teambased care, community involvement, patient registries, and embedded decision support tools to meet patient needs B Physicians, nurse practitioners, physician s assistants, nurses, dietitians, pharmacists, mental health professionals, CDE In this collaborative and integrated team approach, essential that individuals with diabetes assume an active role in their care ADA. 1. Strategies for Improving Diabetes Care. Diabetes Care 2015;38(suppl 1):S5
10 CLASSIFICATION AND DIAGNOSIS OF DIABETES
11 Type 1 diabetes β-cell destruction Type 2 diabetes Classification of Diabetes Progressive insulin secretory defect Other specific types of diabetes Genetic defects in β-cell function, insulin action (MODY) Diseases of the exocrine pancreas (CFRD) Drug- or chemical-induced Gestational diabetes mellitus (GDM) ADA. 2. Classification and Diagnosis. Diabetes Care 2015;38(suppl 1):S8
12 Criteria for the Diagnosis of Diabetes A1C 6.5% OR Fasting plasma glucose (FPG) 126 mg/dl (7.0 mmol/l) OR 2-h plasma glucose 200 mg/dl (11.1 mmol/l) during an OGTT OR A random plasma glucose 200 mg/dl (11.1 mmol/l) ADA. 2. Classification and Diagnosis. Diabetes Care 2015;38(suppl 1):S9; Table 2.1
13 Categories of Increased Risk for Diabetes (Prediabetes)* FPG mg/dl ( mmol/l): IFG OR 2-h plasma glucose in the 75-g OGTT mg/dl ( mmol/l): IGT OR A1C % *For all three tests, risk is continuous, extending below the lower limit of a range and becoming disproportionately greater at higher ends of the range. ADA. 2. Classification and Diagnosis. Diabetes Care 2015;38(suppl 1):S10; Table 2.3
14 Recommendations: Testing for Diabetes in Asymptomatic Patients Consider testing overweight/obese adults (BMI 25 kg/m 2 or 23 kg/m 2 in Asian Americans) with one or more additional risk factors for type 2 diabetes; for all patients, particularly those who are overweight, testing should begin at age 45 years B If tests are normal, repeat testing at least at 3-year intervals is reasonable C To test for diabetes/prediabetes, the A1C, FPG, or 2-h 75-g OGTT are appropriate B In those with prediabetes, monitor for development of diabetes annually E ADA. 2. Classification and Diagnosis. Diabetes Care 2015;38(suppl 1):S11
15 PREVENTION/DELAY OF TYPE 2 DIABETES
16 Recommendations: Prevention/Delay of Type 2 Diabetes Diabetes Prevention Program Targeting weight loss of 7% of body weight Increasing physical activity to at least 150 min/week of moderate activity (eg, walking) Follow-up counseling appears to be important for success Based on cost-effectiveness of diabetes prevention, such programs should be covered by third-party payers ADA. 5. Prevention/Delay of Type 2 Diabetes. Diabetes Care 2015;38(suppl 1):S31
17 GLYCEMIC TARGETS
18 Diabetes Care: Glycemic Control Two primary techniques available for health providers and patients to assess effectiveness of management plan on glycemic control Patient self-monitoring of blood glucose (SMBG), or interstitial glucose A1C Perform the A1C test at least two times a year in patients meeting treatment goals (and have stable glycemic control) Perform the A1C test quarterly in patients whose therapy has changed or who are not meeting glycemic goals ADA. 6. Glycemic Targets. Diabetes Care 2015;38(suppl 1):S33
19 Approach to the Management of Hyperglycemia ADA. 6. Glycemic Targets. Diabetes Care 2015;38(suppl 1):S37. Figure 6.1; adapted with permission from Inzucchi SE, et al. Diabetes Care, 2015;38:
20 Recommendations: Glycemic Goals in Adults (1) Lowering A1C to below or around 7% has been shown to reduce microvascular complications and, if implemented soon after the diagnosis of diabetes, is associated with long-term reduction in macrovascular disease. Therefore, a reasonable A1C goal for many nonpregnant adults is <7% Providers might reasonably suggest more stringent A1C goals (such as <6.5%) for selected individual patients, if this can be achieved without significant hypoglycemia ADA. 6. Glycemic Targets. Diabetes Care 2015;38(suppl 1):S35
21 Recommendations: Glycemic Goals in Adults (2) Less stringent A1C goals (such as <8%) may be appropriate for patients with History of severe hypoglycemia, limited life expectancy, advanced microvascular or macrovascular complications, extensive comorbid conditions Those with longstanding diabetes in whom the general goal is difficult to attain despite DSME, appropriate glucose monitoring, and effective doses of multiple glucose lowering agents including insulin ADA. 6. Glycemic Targets. Diabetes Care 2015;38(suppl 1):S35
22 APPROACHES TO GLYCEMIC TREATMENT
23 Recommendations: Pharmacological Therapy For Type 1 Diabetes Most people with type 1 diabetes should: Be treated with MDI injections (3 4 injections per day of basal and prandial insulin) or continuous subcutaneous insulin infusion (CSII) A Be educated in how to match prandial insulin dose to carbohydrate intake, premeal blood glucose, and anticipated activity E Use insulin analogs to reduce hypoglycemia risk A ADA. 7. Approaches to Glycemic Treatment. Diabetes Care 2015;38(suppl 1):S41
24 Recommendations: Pharmacological Therapy For Type 2 Diabetes (1) Metformin, if not contraindicated and if tolerated, is the preferred initial pharmacological agent for type 2 diabetes A ADA. 7. Approaches to Glycemic Treatment. Diabetes Care 2015;38(suppl 1):S42
25 Recommendations: Therapy for Type 2 Diabetes (2) A patient-centered approach should be used to guide choice of pharmacological agents Considerations include efficacy, cost, potential side effects, effects on weight, comorbidities, hypoglycemia risk, and patient preferences E Due to the progressive nature of type 2 diabetes, insulin therapy is eventually indicated for many patients with type 2 diabetes B Overall each class of noninsulin agent decreases A1c by % ADA. 7. Approaches to Glycemic Treatment. Diabetes Care 2015;38(suppl 1):S41
26 Antihyperglycemic Therapy in Type 2 Diabetes ADA. 7. Approaches to Glycemic Treatment. Diabetes Care 2015;38(suppl 1):S43. Figure 7.1; adapted with permission from Inzucchi SE, et al. Diabetes Care, 2015;38:
27 Approach To Starting and Adjusting Insulin in Type 2 Diabetes ADA. 7. Approaches to Glycemic Treatment. Diabetes Care 2015;38(suppl 1):S46. Figure 7.2; adapted with permission from Inzucchi SE, et al. Diabetes Care, 2015;38:
28 Case 58 yo M has had DM2 for 16 yrs, poorly controlled. Current regimen below. [+] MI and CHF. [+] retinopathy and gastroparesis. No hypoglycemia. Nonsmoker. [+] family history. BP 138/90, BMI 34. Lungs clear. [+] BLE edema. Metformin 1000mg BID Glipizide 10mg BID Atorvastatin 40 mg daily
29 Case - continued Hemoglobin A 1c = 8.4% Creatinine = 0.67 mg/dl TSH = 2.83 miu/l LDL cholesterol = 92 mg/dl
30 Case - continued Addition of which medication below will improve glucose control and minimize side effects? A. Exenetide B. Pioglitazone C. Saxagliptin D. Canagliflozin E. Insulin glargine
31 Thiazolidinediones Pioglitazone, Rosiglitazone Activates nuclear transcription factor PPAR-γ, increasing insulin sensitivity Pros: Cons: No hypoglycemia,? Decreased CVD (pio), generic Wt increase, edema, CHF,? MI (rosi)
32 Glucagon-like-peptide-1 agonists Exenetide, exenetide extended release, liraglutide, albiglutide, dulaglutide Increases glucose dependent insulin secretion, increases satiety, slows gastric emptying Pros: No hypoglycemia, Dec wt, Dec postprand gluc Cons: GI side effects,?pancreatitis, medullary thyroid cancer, cost
33 Dipeptidyl peptidase-4 inhibitors Sitagliptin, saxagliptin, linagliptin, alogliptin DPP-4 breaks down GLP-1 Results in increased glucose dependent insulin secretion Pros: No hypoglycemia, oral Cons:?increased CHF,?acute pancreatitis, angioedema, cost
34 Sodium-glucose Cotransporter 2 inhibitors Canagliflozin, dapagliflozin, empagliflozin Inihibits SGLT-2 in the proximal nephron, leading to glucosuria Pros: Cons: No hypoglycemia, wt loss, decreased BP GU infections, polyuria, hypotension, dehydration, increased LDL, cost
35 Insulins (onset / duration) Rapid acting (15 / 3-5h) Lispro Aspart Glulisine Inhaled insulin (15 / 2h) Short acting (30-60 / 4-8h) Human regular Intermediate Human NPH (2-4h / 10-18h) U-500 regular (30-60 / 10-18h)
36 Insulins (onset / duration) Basal insulin analogs Lantus (Glargine U-100) (4-6h / 24h) Detemir (2-3h / 6-24h) Toujeo (Glargine U-300) (6h / 24h) Pre-mixed insulins 70/30 75/25 50/50
37 Case 58 yo M has had DM2 for 2 yrs, poorly controlled. Current regimen below. No complications. No hypoglycemia. Nonsmoker. [+] family history. BP 128/60, BMI 31. Exam otherwise normal. Metformin 1000mg BID Glipizide 10mg BID Atorvastatin 40 mg daily
38 Case - continued Hemoglobin A 1c = 11.4% Creatinine = 0.67 mg/dl LDL cholesterol = 92 mg/dl
39 Case - continued Addition of which medication below will improve glucose control and minimize side effects? A. Liraglutide B. Pioglitazone C. Linagliptin D. Canagliflozin E. Insulin detemir
40 CARDIOVASCULAR DISEASE AND RISK MANAGEMENT
41 Cardiovascular Disease CVD is the major cause of morbidity, mortality for those with diabetes Largest contributor to direct/indirect costs Common conditions coexisting with type 2 diabetes (e.g., hypertension, dyslipidemia) are clear risk factors for CVD Diabetes itself confers independent risk Benefits observed when individual cardiovascular risk factors are controlled to prevent/slow CVD in people with diabetes ADA. 8. Cardiovascular Disease and Risk Management. Diabetes Care 2015;38(suppl 1):S49
42 Recommendations: Hypertension/Blood Pressure Control Goals People with diabetes and hypertension should be treated to a systolic blood pressure goal of <140 mmhg A Lower systolic targets, such as <130 mmhg, may be appropriate for certain individuals, such as younger patients, if it can be achieved without undue treatment burden C Patients with diabetes should be treated to a diastolic blood pressure <90 mmhg A Lower diastolic targets, such as <80 mmhg, may be appropriate for certain individuals, such as younger patients, if it can be achieved without undue treatment burden B ADA. 8. Cardiovascular Disease and Risk Management. Diabetes Care 2015;38(suppl 1):S49
43 Recommendations: Hypertension/Blood Pressure Control Treatment Pharmacological therapy for patients with diabetes and hypertension comprise a regimen that includes either an ACE inhibitor or angiotensin II receptor blocker B; if one class is not tolerated, substitute the other C An ACE inhibitor or ARB is not recommended for the primary prevention of diabetic kidney disease in patients who have normal blood pressure and a normal urine-albumin-tocreatinine ratio (UACR) (<30 mg/g) B ADA. 8. Cardiovascular Disease and Risk Management. Diabetes Care 2015;38(suppl 1):S50
44 Recommendations: Dyslipidemia/Lipid Management Screening In adults, a screening lipid profile is reasonable E At first diagnosis At the initial medical evaluation And/or at age 40 years and periodically (e.g., every 1-2 years) thereafter ADA. 8. Cardiovascular Disease and Risk Management. Diabetes Care 2015;38(suppl 1):S51
45 Case 19 yo M has had DM1 for 8 yrs, reasonable control managed on MDI insulin regimen. No complications. Rare hypoglycemia. Nonsmoker. [-] family history. BP 128/78, BMI 32 otherwise normal exam.
46 Case - continued Hemoglobin A 1c = 7.8% Creatinine = 0.77 mg/dl TSH = 2.83 miu/l Total cholesterol = 224 mg/dl HDL cholesterol = 26 mg/dl LDL cholesterol = 150 mg/dl Triglycerides = 229 mg/dl
47 Case - continued Initiation of which of the following would lead to greatest reduction in lifetime cardiovascular risk? A. Intensify glucose control B. Statin C. Fibrate D. Niacin E. Low fat diet
48 Recommendations for Statin Treatment in People with Diabetes Age Risk factors Recommended statin dose * Monitoring with lipid panel <40 years None None Annually or as CVD risk factor(s) ** Moderate or high needed to monitor for Overt CVD *** High adherence years >75 years None Moderate As needed to CVD risk factors High monitor Overt CVD High adherence None CVD risk factors Overt CVD Moderate Moderate or high High As needed to monitor adherence * In addition to lifestyle therapy. ** CVD risk factors include LDL cholesterol 100 mg/dl (2.6 mmol/l), high blood pressure, smoking, and overweight and obesity. *** Overt CVD includes those with previous cardiovascular events or acute coronary syndromes. ADA. 8. Cardiovascular Disease and Risk Management. Diabetes Care 2015;38(suppl 1):S52, Table 8.1
49 What is moderate / high intensity statin? Circulation. June 24, 2014 vol. 129 no. 25 suppl 2 S1-S45
50 Recommendations: Dyslipidemia/Lipid Management Treatment recommendations and goals Combination therapy has been shown not to provide additional cardiovascular benefit above statin therapy alone and is not generally recommended A Statin therapy is contraindicated in pregnancy B In clinical practice, providers may need to adjust intensity of statin therapy based on individual patient response to medication (e.g. side effects, tolerability, LDL cholesterol levels.) E Cholesterol laboratory testing may be helpful in monitoring adherence to therapy but may not be needed once the patient is stable on therapy E ADA. 8. Cardiovascular Disease and Risk Management. Diabetes Care 2015;38(suppl 1):S52
51 Questions?
Standards of Medical Care In Diabetes
Standards of Medical Care In Diabetes - 2017 Robert E. Ratner, MD, FACP, FACE Professor of Medicine Georgetown University School of Medicine Disclosed no conflict of interest Standards of Care Professional.diabetes.org/SOC
More informationStandards of Medical Care in Diabetes 2016
Standards of Medical Care in Diabetes 2016 Care Delivery Systems 33-49% of patients still do not meet targets for A1C, blood pressure, or lipids. 14% meet targets for all A1C, BP, lipids, and nonsmoking
More informationWayne Gravois, MD August 6, 2017
Wayne Gravois, MD August 6, 2017 Americans with Diabetes (Millions) 40 30 Source: National Diabetes Statistics Report, 2011, 2017 Millions 20 10 0 1980 2009 2015 2007 - $174 Billion 2015 - $245 Billion
More informationSTANDARDS OF MEDICAL CARE IN DIABETES 2014
STANDARDS OF MEDICAL CARE IN DIABETES 2014 I. CLASSIFICATION AND DIAGNOSIS Classification of Diabetes Type 1 diabetes β-cell destruction Type 2 diabetes Progressive insulin secretory defect Other specific
More informationType 2 Diabetes: Where Do We Start with Treatment? DIABETES EDUCATION. Diabetes Mellitus: Complications and Co-Morbid Conditions
Diabetes Mellitus: Complications and Co-Morbid Conditions ADA Guidelines for Glycemic Control: 2016 Retinopathy Between 2005-2008, 28.5% of patients with diabetes 40 years and older diagnosed with diabetic
More informationDiabetes Mellitus II CPG
1 Diabetes Mellitus II CPG Candidates for Screening Integrated Complex Care Patients: Check Yearly Prediabetes: Check Yearly No Diabetes Mellitus (DM) Risk Factors: Check at Age 45, Repeat Every 3 Years
More informationThe Many Faces of T2DM in Long-term Care Facilities
The Many Faces of T2DM in Long-term Care Facilities Question #1 Which of the following is a risk factor for increased hypoglycemia in older patients that may suggest the need to relax hyperglycemia treatment
More informationAbbreviations DPP-IV dipeptidyl peptidase IV DREAM Diabetes REduction Assessment with ramipril and rosiglitazone
Index Abbreviations DPP-IV dipeptidyl peptidase IV DREAM Diabetes REduction Assessment with ramipril and rosiglitazone Medication GAD glutamic acid decarboxylase GLP-1 glucagon-like peptide 1 NPH neutral
More informationOral Hypoglycemics and Risk of Adverse Cardiac Events: A Summary of the Controversy
Oral Hypoglycemics and Risk of Adverse Cardiac Events: A Summary of the Controversy Jeffrey Boord, MD, MPH Advances in Cardiovascular Medicine Kingston, Jamaica December 7, 2012 VanderbiltHeart.com Outline
More informationDiabetes Review Chris Paras, D.O. Assistant Prof of Medicine, NYIT & Touro COM Designated Institutional Official & Assoc. Clinical Dean, Brookdale
Diabetes Review Chris Paras, D.O. Assistant Prof of Medicine, NYIT & Touro COM Designated Institutional Official & Assoc. Clinical Dean, Brookdale University Hospital Diabetes Care 2018 Jan; 41 Objectives
More informationModified version focused on CCNC Quality Measures and Feedback Processes
Executive Summary: Standards of Medical Care in Diabetes 2010 Modified version focused on CCNC Quality Measures and Feedback Processes See http://care.diabetesjournals.org/content/33/supplement_1/s11.full
More informationDisclosures. Diabetes and Cardiovascular Risk Management. Learning Objectives. Atherosclerotic Cardiovascular Disease
Disclosures Diabetes and Cardiovascular Risk Management Tony Hampton, MD, MBA Medical Director Advocate Aurora Operating System Advocate Aurora Healthcare Downers Grove, IL No conflicts or disclosures
More informationNEW DIABETES CARE MEDICATIONS
NEW DIABETES CARE MEDICATIONS James Bonucchi DO, ECNU, FACE Adult Medicine and Endocrinology Specialists Disclosures Speakers bureau Sanofi AZ BI Diabetes Diabetes cost ADA 2017 data Ever increasing disorder.
More informationDiabetes Risk Assessment and Treatment
Diabetes Risk Assessment and Treatment Todd T. Brown, MD, PhD Professor of Medicine and Epidemiology Division of Endocrinology, Diabetes, & Metabolism Johns Hopkins University Baltimore, Maryland, USA
More informationA Practical Approach to the Use of Diabetes Medications
A Practical Approach to the Use of Diabetes Medications Juan Pablo Frias, M.D., FACE President, National Research Institute, Los Angles, CA Clinical Faculty, University of California, San Diego, CA OUTLINE
More informationJanice Lazear, DNP, FNP-C, CDE DIAGNOSIS AND CLASSIFICATION OF DIABETES
Janice Lazear, DNP, FNP-C, CDE DIAGNOSIS AND CLASSIFICATION OF DIABETES Objectives u At conclusion of the lecture the participant will be able to: 1. Differentiate between the classifications of diabetes
More informationAmerican Diabetes Association 2018 Guidelines Important Notable Points
American Diabetes Association 2018 Guidelines Important Notable Points The Standards of Medical Care in Diabetes-2018 by ADA include the most current evidencebased recommendations for diagnosing and treating
More informationClinical Practice Guidelines
Clinical Practice Guidelines Diabetes Objective The purpose is to guide the appropriate diagnosis and management of Diabetes. This guideline is designed to assist the clinician by providing a framework
More informationAdult Diabetes Clinician Guide NOVEMBER 2017
Kaiser Permanente National CLINICAL PRACTICE GUIDELINES Adult Diabetes Clinician Guide Introduction NOVEMBER 2017 This evidence-based guideline summary is based on the 2017 KP National Diabetes Guideline.
More informationExecutive Summary: Standards of Medical Care in Diabetes 2010
E X E C U T I V E S U M M A R Y Executive Summary: Standards of Medical Care in Diabetes 2010 Current criteria for the diagnosis of diabetes A1C 6.5%: The test should be performed in a laboratory using
More informationSTANDARDS OF MEDICAL CARE IN DIABETES 2012
STANDARDS OF MEDICAL CARE IN DIABETES 2012 Section Table of Contents ADA Evidence Grading System of Clinical Recommendations Slide No. I. Classification and Diagnosis 4-11 II. Testing for Diabetes in Asymptomatic
More informationCardiovascular Benefits of Two Classes of Antihyperglycemic Medications
Cardiovascular Benefits of Two Classes of Antihyperglycemic Medications Nathan Woolever, Pharm.D., Resident Pharmacist Pharmacy Grand Rounds November 6 th, 2018 Franciscan Healthcare La Crosse, WI 2017
More informationDiabetes Mellitus: Implications of New Clinical Trials and New Medications
Diabetes Mellitus: Implications of New Clinical Trials and New Medications Estimates of Diagnosed Diabetes in Adults, 2005 Alka M. Kanaya, MD Asst. Professor of Medicine UCSF, Primary Care CME October
More informationIndividualizing Care for Patients with Type 2 Diabetes
Individualizing Care for Patients with Type 2 Diabetes Disclosures Speaker: AstraZeneca, Novo Nordisk, BI/Lilly, Valeritas, Takeda Advisor: Tandem Diabetes, Sanofi Objectives Develop individualized approaches
More informationDiabetes 2013: Achieving Goals Through Comprehensive Treatment. Session 2: Individualizing Therapy
Diabetes 2013: Achieving Goals Through Comprehensive Treatment Session 2: Individualizing Therapy Joshua L. Cohen, M.D., F.A.C.P. Professor of Medicine Interim Director, Division of Endocrinology & Metabolism
More informationWhat s New in Diabetes Medications. Jena Torpin, PharmD
What s New in Diabetes Medications Jena Torpin, PharmD 1 Objectives Discuss new medications in the management of diabetes Understand the mechanism of the medications discussed Understand the side effects
More informationComprehensive Diabetes Treatment
Comprehensive Diabetes Treatment Joshua L. Cohen, M.D., F.A.C.P. Professor of Medicine Interim Director, Division of Endocrinology & Metabolism The George Washington University School of Medicine Diabetes
More informationQuick Reference Guide
2013 Clinical Practice Guidelines Quick Reference Guide (Updated November 2016) 416569-16 guidelines.diabetes.ca diabetes.ca 1-800-BANTING (226-8464) Copyright 2016 Canadian Diabetes Association SCREENING
More informationExecutive Summary: Standards of Medical Care in Diabetes 2009
Executive Summary Executive Summary: Standards of Medical Care in Diabetes 2009 Current Criteria for the Diagnosis of Diabetes Fasting plasma glucose (FPG) 126 mg/dl (7.0 mmol/l). Fasting is defined as
More informationIMPROVED DIAGNOSIS OF TYPE 2 DIABETES AND TAILORING MEDICATIONS
IMPROVED DIAGNOSIS OF TYPE 2 DIABETES AND TAILORING MEDICATIONS Dr Bidhu Mohapatra, MBBS, MD, FRACP Consultant Physician Endocrinology and General Medicine Introduction 382 million people affected by diabetes
More informationDiabetes Update: Diabetes Management In Primary Care. Jonathon M. Firnhaber, MD, FAAFP
Diabetes Update: Diabetes Management In Primary Care Jonathon M. Firnhaber, MD, FAAFP Learning objectives 1. Critically evaluate the evidence emerging within diabetes research as it applies to recommendations
More informationThe ABCs (A1C, BP and Cholesterol) of Diabetes
The ABCs (A1C, BP and Cholesterol) of Diabetes Gregg Simonson, PhD Director, Professional Training and Consulting International Diabetes Center; Adjunct Assistant Professor, University of Minnesota Department
More informationStandards of Medical Care in Diabetes 2018
Standards of Medical Care in Diabetes 2018 Eric L. Johnson, M.D. Associate Professor University of North Dakota School of Medicine and Health Sciences Assistant Medical Director Altru Diabetes Center Grand
More informationClinical Practice Guidelines for Diabetes Management
Clinical Practice Guidelines for Diabetes Management Diabetes is a disease in which blood glucose levels are above normal. Over the years, high blood glucose damages nerves and blood vessels, which can
More informationInitiation and Titration of Insulin in Diabetes Mellitus Type 2
Initiation and Titration of Insulin in Diabetes Mellitus Type 2 Greg Doelle MD, MS April 6, 2016 Disclosure I have no actual or potential conflicts of interest in relation to the content of this lecture.
More informationWhat s New in Diabetes Treatment. Disclosures
What s New in Diabetes Treatment Shiri Levy M.D. Henry Ford Hospital Senior Staff Physician Service Chief, West Bloomfield Hospital Endocrinology, Metabolism, Bone and Mineral Disorders Disclosures None
More informationKey Elements in Managing Diabetes
Key Elements in Managing Diabetes Presentor Disclosure No conflicts of interest to disclose Presented by Susan Cotey, RN, CDE Lennon Diabetes Center Stephanie Tubbs Jones Health Center Cleveland Clinic
More informationUpdates in Diabetes Management. Virginia Society of Health-System Pharmacists Annual Spring Seminar Angela Hamilton, PharmD, BCPS April 18, 2015
Updates in Diabetes Management Virginia Society of Health-System Pharmacists Annual Spring Seminar Angela Hamilton, PharmD, BCPS April 18, 2015 Disclosure Statement Conflict of Interest Nothing to Disclose
More informationStandards of Care in Diabetes What's New? Veronica Brady, FNP-BC, PhD, BC-ADM,CDE Karmella Thomas, RD, LD,CDE
Standards of Care in Diabetes 2016-- What's New? Veronica Brady, FNP-BC, PhD, BC-ADM,CDE Karmella Thomas, RD, LD,CDE Terminology No longer using the term diabetic. Diabetes does not define people. People
More informationInsulin Initiation and Intensification. Disclosure. Objectives
Insulin Initiation and Intensification Neil Skolnik, M.D. Associate Director Family Medicine Residency Program Abington Memorial Hospital Professor of Family and Community Medicine Temple University School
More informationReviewing Diabetes Guidelines. Newsletter compiled by Danny Jaek, Pharm.D. Candidate
Reviewing Diabetes Guidelines Newsletter compiled by Danny Jaek, Pharm.D. Candidate AL AS KA N AT IV E DI AB ET ES TE A M Volume 6, Issue 1 Spring 2011 Dia bet es Dis pat ch There are nearly 24 million
More informationType 2 Diabetes Mellitus 2011
2011 Michael T. McDermott MD Director, Endocrinology and Diabetes Practice University of Colorado Hospital Michael.mcdermott@ucdenver.edu Diabetes Mellitus Diagnosis 2011 Diabetes Mellitus Fasting Glucose
More informationCURRENT ISSUES IN DIABETES MANAGEMENT. Screening for Diabetes Advantages of HbA1c as a Diagnostic Test. Diagnosis of Diabetes 2013
CURRENT ISSUES IN DIABETES MANAGEMENT Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of interest Screening for Diabetes 2013 BMI
More information7/8/2016. Sol Jacobs MD, FACE Division of Endocrinology Emory University School of Medicine
Sol Jacobs MD, FACE Division of Endocrinology Emory University School of Medicine Participation in investigator initiated clinical research supported by: Merck Boehringer Ingelheim Novo Nordisk Astra Zeneca
More informationChief of Endocrinology East Orange General Hospital
Targeting the Incretins System: Can it Improve Our Ability to Treat Type 2 Diabetes? Darshi Sunderam, MD Darshi Sunderam, MD Chief of Endocrinology East Orange General Hospital Age-adjusted Percentage
More informationIndividualizing Type 2 Diabetes Management. Cynthia Gerstenlauer, ANP-BC, GCNS-BC, CDE, CCD
Individualizing Type 2 Diabetes Management Cynthia Gerstenlauer, ANP-BC, GCNS-BC, CDE, CCD Harsh Statistics 30.3 million (9.4% of population) in US had DM in 2015 The percent of population with DM increases
More informationManagement of Hyperglycemia in Type 2 Diabetes Celeste C. Thomas MD, MS
Management of Hyperglycemia in Type 2 Diabetes Celeste C. Thomas MD, MS Disclosures In compliance with the accrediting board policies, the American Diabetes Association requires the following disclosure
More information3/28/ Diabetes Clinical Practice Recommendations and Treatment Algorithms: What s New! Epidemiology of Diabetes. Outline
2013 Diabetes Clinical Practice Recommendations and Treatment Algorithms: What s New! The speaker has no conflict in relation to this program. David W. Bartels, PharmD, CDE Vice Dean and Clinical Professor
More informationManagement of Diabetes
Management of Diabetes Mellitus: Which Drugs for Which Patients? Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine baron@medicine.ucsf.edu Disclosure No relevant financial relationships
More informationInitiating Injectable Therapy in Type 2 Diabetes
Initiating Injectable Therapy in Type 2 Diabetes David Doriguzzi, PA C Learning Objectives To understand current Diabetes treatment guidelines To understand how injectable medications fit into current
More informationAmerican Diabetes Association: Standards of Medical Care in Diabetes 2015
American Diabetes Association: Standards of Medical Care in Diabetes 2015 Synopsis of ADA standards relevant to the 11 th Scope of Work under Task B.2 ASSESSMENT OF GLYCEMIC CONTROL Recommendations: Perform
More informationGLP-1 (glucagon-like peptide-1) Agonists (Byetta, Bydureon, Tanzeum, Trulicity, Victoza ) Step Therapy and Quantity Limit Criteria Program Summary
OBJECTIVE The intent of the GLP-1 (glucagon-like peptide-1) s (Byetta/exenatide, Bydureon/ exenatide extended-release, Tanzeum/albiglutide, Trulicity/dulaglutide, and Victoza/liraglutide) Step Therapy
More informationOlder Adults & Optimal Outcome. Individualizing Diabetes Management. Mary Moyer Janci BC-FNP BC-ADM CDE Teaching Associate Diabetes Care Center UWMC
Older Adults & Optimal Outcome Individualizing Diabetes Management Mary Moyer Janci BC-FNP BC-ADM CDE Teaching Associate Diabetes Care Center UWMC What is Diabetes? METABOLIC DISEASE Food breakdown (carbohydrates,
More informationDiabetes Summary of Medical Guidelines
Diabetes Summary of Medical Guidelines Key concepts in setting glycemic controls: goals should be individualized; certain populations (children, pregnant women, and elderly) require special considerations;
More informationDr Aftab Ahmad Consultant Diabetologist at Royal Liverpool University Hospital Regional Diabetes Network Lead
Dr Aftab Ahmad Consultant Diabetologist at Royal Liverpool University Hospital Regional Diabetes Network Lead Today s Presentation HbA1c & diagnosing Diabetes What is Impaired Glucose & IGR? Implications
More informationQuick Reference Guide
2018 Clinical Practice Guidelines Quick Reference Guide 416569-18 guidelines.diabetes.ca diabetes.ca 1-800-BANTING (226-8464) Screening and Diagnosis Assess risk ANNUALLY if: Family history (First-degree
More informationThe Death of Sulfonylureas? A Review of New Diabetes Medications
The Death of Sulfonylureas? A Review of New Diabetes Medications Kelly Hoenig, Pharm.D., BCPS Cedar Rapids Family Medicine Residency 2/4/17 Objectives Review GLP-1 Agonists, DPP-IV Inhibitors and SGLT-2
More informationJoslin Diabetes Center Joslin Diabetes Forum 2013: The Impact of Comorbidities on Glucose Control Scenario 2: Reduced Renal Function
Scenario 2: Reduced Renal Function 62 y.o. white man with type 2 diabetes for 18 years Hypertension and hypercholesterolemia Known proliferative retinopathy Current medications: Metformin 1000 mg bid Glyburide
More informationDiabetes Mellitus case studies. Jana Vinklerová
Diabetes Mellitus case studies Jana Vinklerová Definition of diabetes (metabolic disorder) Chronically raised blood glucose (hyperglycaemia) Insulin/Glucagon Insulin is responsible for lowering glucose
More informationEugene Barrett M.D., Ph.D. University of Virginia 6/18/2007. Diagnosis and what is it Glucose Tolerance Categories FPG
Diabetes Mellitus: Update 7 What is the unifying basis of this vascular disease? Eugene J. Barrett, MD, PhD Professor of Internal Medicine and Pediatrics Director, Diabetes Center and GCRC Health System
More informationCardiovascular Management of a Patient with Diabetes
Cardiovascular Management of a Patient with Diabetes Dr Jeremy Krebs Clinical Leader Endocrinology and Diabetes Wellington Hospital Summary People with diabetes take a lot of medication Compliance and
More informationBeyond Basal Insulin: Intensification of Therapy Jennifer D Souza, PharmD, CDE, BC-ADM
Beyond Basal Insulin: Intensification of Therapy Jennifer D Souza, PharmD, CDE, BC-ADM Disclosures Jennifer D Souza has no conflicts of interest to disclose. 2 When Basal Insulin Is Not Enough Learning
More informationNATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE. Single Technology Appraisal. Canagliflozin in combination therapy for treating type 2 diabetes
NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Single Technology Appraisal Canagliflozin in combination therapy for Final scope Remit/appraisal objective To appraise the clinical and cost effectiveness
More informationWhat s New on the Horizon: Diabetes Medication Update
What s New on the Horizon: Diabetes Medication Update Outline of Talk Newly released and upcoming medications: the incretins, DPP-IV inhibitors, and what s coming Revised ADA/EASD and AACE guidelines:
More informationAntihyperglycemic Agents in Diabetes. Jamie Messenger, PharmD, CPP Department of Family Medicine East Carolina University August 18, 2014
Antihyperglycemic Agents in Diabetes Jamie Messenger, PharmD, CPP Department of Family Medicine East Carolina University August 18, 2014 Objectives Review 2014 ADA Standards of Medical Care in DM as they
More informationOBJECTIVES 4/7/2014. Diabetes Update Overview of the Diabetes Epidemic in the United States. ISHP Annual Spring Meeting
Diabetes Update 2014 ISHP Annual Spring Meeting Hayley Miller MD April 13, 2014 OBJECTIVES Review diabetes guidelines. Understand diabetes management targets. Discuss current therapeutic strategies. Overview
More informationAdvanced Practice Education Associates. Endocrine
Advanced Practice Education Associates Endocrine Overview Diabetes Thyroid Disease 162 Copyright 2016 Advanced Practice Education Associates DIABETES MELLITUS What is the BMI cut point for screening adults
More informationWhat s New on the Horizon: Diabetes Medication Update. Michael Shannon, MD Providence Endocrinology, Olympia WA
What s New on the Horizon: Diabetes Medication Update Michael Shannon, MD Providence Endocrinology, Olympia WA 1 Outline of Talk Newly released and upcoming medications: the incretins, DPP-IV inhibitors,
More informationPresenter Disclosure Information
Prediabetes & Type 2 Diabetes Prevention Cari Ritter, PA-C Presenter Disclosure Information In compliance with the accrediting board policies, the American Diabetes Association requires the following disclosure
More informationCURRENT CONTROVERSIES IN DIABETES CARE
CURRENT CONTROVERSIES IN DIABETES CARE Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of interest Diabetes Mellitus: U.S. Impact
More informationObesity, Insulin Resistance, Metabolic Syndrome, and the Natural History of Type 2 Diabetes
Obesity, Insulin Resistance, Metabolic Syndrome, and the Natural History of Type 2 Diabetes Genetics, environment, and lifestyle (obesity, inactivity, poor diet) Impaired fasting glucose Decreased β-cell
More informationPractical Strategies for the Clinical Use of Incretin Mimetics CME/CE. CME/CE Released: 09/15/2009; Valid for credit through 09/15/2010
Practical Strategies for the Clinical Use of Incretin Mimetics CME/CE Robert R. Henry, MD Authors and Disclosures CME/CE Released: 09/15/2009; Valid for credit through 09/15/2010 Introduction Type 2 diabetes
More informationYOU HAVE DIABETES. Angie O Connor Community Diabetes Nurse Specialist 25th September 2013
YOU HAVE DIABETES Angie O Connor Community Diabetes Nurse Specialist 25th September 2013 Predicated 2015 figures are already met 1 in 20 have diabetes:1in8 over 60years old Definite Diagnosis is key Early
More informationPharmacology Updates. Quang T Nguyen, FACP, FACE, FTOS 11/18/17
Pharmacology Updates Quang T Nguyen, FACP, FACE, FTOS 11/18/17 14 Classes of Drugs Available for the Treatment of Type 2 DM in the USA ### Class A1c Reduction Hypoglycemia Weight Change Dosing (times/day)
More informationWhat s New in Type 2 Diabetes? 2018 Diabetes Updates
What s New in Type 2 Diabetes? 2018 Diabetes Updates Gretchen Ray, PharmD, PhC, BCACP, CDE Associate Professor, UNM College of Pharmacy January 28, 2018 gray@salud.unm.edu OBJECTIVES Describe the most
More informationMultiple Factors Should Be Considered When Setting a Glycemic Goal
Multiple Facts Should Be Considered When Setting a Glycemic Goal Patient attitude and expected treatment effts Risks potentially associated with hypoglycemia, other adverse events Disease duration Me stringent
More informationDiabetes Mellitus: Evaluation and Care Management
Diabetes Mellitus: Evaluation and Care Management Michael King, MD Assistant Professor Residency Program Director University of Kentucky Dept. of Family & Community Medicine Learning Objectives 1. Review
More informationDiabetes Mellitus in Older Adults. Presenter Disclosure Information
Diabetes Mellitus in Older Adults Medha Munshi, M.D. Joslin Diabetes Center Beth Israel Deaconess Medical Center Harvard Medical School Presenter Disclosure Information Medha Munshi Research grant from
More informationNew Therapies for Diabetes Management: Hope or Headache?
New Therapies for Diabetes Management: Hope or Headache? Elizabeth Stephens, MD, FACP PMG- Endocrinology Elizabeth.Stephens@providence.org November 2018 Disclosures None 1 Objectives Discussion of 3 rd
More informationNewer Drugs in the Management of Type 2 Diabetes Mellitus
Newer Drugs in the Management of Type 2 Diabetes Mellitus Dr. C. Dinesh M. Naidu Professor of Pharmacology, Kamineni Institute of Medical Sciences, Narketpally. 1 Presentation Outline Introduction Pathogenesis
More informationNon-insulin treatment in Type 1 DM Sang Yong Kim
Non-insulin treatment in Type 1 DM Sang Yong Kim Chosun University Hospital Conflict of interest disclosure None Committee of Scientific Affairs Committee of Scientific Affairs Insulin therapy is the mainstay
More informationDiabetes in Pregnancy
Diabetes in Pregnancy Ebony Boyce Carter, MD, MPH Division of Maternal Fetal Medicine Washington University School of Medicine Disclosures I have no financial disclosures to report. Objectives Review the
More information11/4/2014. Outline. Pharmacists Objectives. Diabetes Update: What s New in Pharmacy Technician Objectives. Overview: Type 2 Diabetes Mellitus
Diabetes Update: What s New in 2014 Dr. Amy P. Witte, Pharm.D. Associate Professor, Pharmacy Practice UIW Feik School of Pharmacy CTSHP Fall Seminar La Cantera Hill Country Resort October 25, 2014 Pharmacists
More informationRCHC Clinical Guidelines Type 2 Diabetes; Adults
RCHC Clinical Guidelines Type 2 Diabetes; Adults Screening for diabetes in asymptomatic adults 1 Population: Aged > 45 years; Aged < 45 years who are overweight (BMI> 25kg/m 2 ) and have an additional
More informationDiabetes Oral Agents Pharmacology. University of Hawai i Hilo Pre-Nursing Program NURS 203 General Pharmacology Danita Narciso Pharm D
Diabetes Oral Agents Pharmacology University of Hawai i Hilo Pre-Nursing Program NURS 203 General Pharmacology Danita Narciso Pharm D 1 Learning Objectives Understand the role of the utilization of free
More informationDiabetes: Definition Pathophysiology Treatment Goals. By Scott Magee, MD, FACE
Diabetes: Definition Pathophysiology Treatment Goals By Scott Magee, MD, FACE Disclosures No disclosures to report Definition of Diabetes Mellitus Diabetes Mellitus comprises a group of disorders characterized
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE. Proposed Health Technology Appraisal
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE Proposed Health Technology Appraisal Dapagliflozin in combination therapy for the Final scope Remit/appraisal objective To appraise the clinical and
More informationPrediabetes: You Can Help Your Patients Exit the Express Lane to Diabetes!
Prediabetes: You Can Help Your Patients Exit the Express Lane to Diabetes! Jaini Patel, PharmD, BCACP Assistant Professor of Pharmacy Practice Midwestern University Chicago College of Pharmacy Kathleen
More informationTable 1. Antihyperglycemic agents for use in type 2 diabetes
Table 1. Antihyperglycemic agents for use in type 2 diabetes DRUG IN ALPHA-GLUCOSIDASE INHIBITOR: inhibits pancreatic alpha-amyle and intestinal alpha-glucoside Acarbose (Glucobay) 0.6% Negligible Not
More informationDiabetes Treatment Update
Diabetes Treatment Update Timothy C. Evans, MD PhD FACP University of Washington Department of Medicine Disclosure: Dr. Evans has no significant financial interest in any of the products or manufacturers
More informationDrug Class Review Newer Diabetes Medications and Combinations
Drug Class Review Newer Diabetes Medications and Combinations Final Update 2 Report July 2016 The purpose reports is to make available information regarding the comparative clinical effectiveness and harms
More informationDiabete: terapia nei pazienti a rischio cardiovascolare
Diabete: terapia nei pazienti a rischio cardiovascolare Giorgio Sesti Università Magna Graecia di Catanzaro Cardiovascular mortality in relation to diabetes mellitus and a prior MI: A Danish Population
More informationDiabetes and New Meds for Cardiovascular Risk Reduction. F. Dwight Chrisman, MD, FACC. Disclosures: BI Boehringer Ingelheim speaker
Diabetes and New Meds for Cardiovascular Risk Reduction F. Dwight Chrisman, MD, FACC Disclosures: BI Boehringer Ingelheim speaker 1 Prevalence of DM DM state specific prevalence 2006 4%-6% 6-8% 8-10% 10-12%
More informationPrediabetes Prediabetes: You Can Help Your Patients Exit the Express Lane to Diabetes! Disclosures/Conflict of Interest.
Prediabetes: You Can Help Your Patients Exit the Express Lane to Diabetes! Jaini Patel, PharmD, BCACP Assistant Professor of Pharmacy Practice Midwestern University Chicago College of Pharmacy Kathleen
More informationCurrent Trends in Diagnosis and Management of Gestational Diabetes
Current Trends in Diagnosis and Management of Gestational Diabetes Shreela Mishra, MD Assistant Clinical Professor UCSF Fresno Medical Education Program 2/2/2019 Disclosures No disclosures 2/2/19 Objectives
More informationDiabetes and Hypertension
Diabetes and Hypertension M.Nakhjvani,M.D Tehran University of Medical Sciences 20-8-96 Hypertension Common DM comorbidity Prevalence depends on diabetes type, age, BMI, ethnicity Major risk factor for
More informationV. N. Karazin Kharkiv National University Department of internal medicine Golubkina E.O., ass. of prof., Shanina I. V., ass. of prof.
V. N. Karazin Kharkiv National University Department of internal medicine Golubkina E.O., ass. of prof., Shanina I. V., ass. of prof., Macharinskaya O.S., ass. of prof; Supervisor: prof. Yabluchanskiy
More informationCase study: Lean adult with no complications, newly diagnosed with type 2 diabetes
Case study: Lean adult with no complications, newly diagnosed with type 2 diabetes Authored by Clifford Bailey and James LaSalle on behalf of the Global Partnership for Effective Diabetes Management. The
More informationThe Diabetes Link to Heart Disease
The Diabetes Link to Heart Disease Anthony Abe DeSantis, MD September 18, 2015 University of WA Division of Metabolism, Endocrinology and Nutrition Oswald Toosweet Case #1 68 yo M with T2DM Diagnosed DM
More informationWhat s New in Type 2 Diabetes? 2018 Diabetes Updates
What s New in Type 2 Diabetes? 2018 Diabetes Updates Jessica Conklin, PharmD, PhC, BCACP, CDE, AAHIP Associate Professor, UNM College of Phar macy jeconklin@salud.unm.edu Luis Gonzales, PharmD, PhC UNM
More information